218 related articles for article (PubMed ID: 21824629)
1. Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach.
Szabó N; Kincses ZT; Toldi J; Vécsei L
J Neurol Sci; 2011 Nov; 310(1-2):256-60. PubMed ID: 21824629
[TBL] [Abstract][Full Text] [Related]
2. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
3. Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia.
Havelund JF; Andersen AD; Binzer M; Blaabjerg M; Heegaard NHH; Stenager E; Faergeman NJ; Gramsbergen JB
J Neurochem; 2017 Sep; 142(5):756-766. PubMed ID: 28628213
[TBL] [Abstract][Full Text] [Related]
4. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
Sas K; Robotka H; Toldi J; Vécsei L
J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
[TBL] [Abstract][Full Text] [Related]
5. Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System.
Majláth Z; Toldi J; Fülöp F; Vécsei L
Curr Med Chem; 2016; 23(9):874-83. PubMed ID: 26872942
[TBL] [Abstract][Full Text] [Related]
6. NMDA antagonists as Parkinson's disease therapy: disseminating the evidence.
Majláth Z; Vécsei L
Neurodegener Dis Manag; 2014; 4(1):23-30. PubMed ID: 24640976
[TBL] [Abstract][Full Text] [Related]
7. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
8. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
[TBL] [Abstract][Full Text] [Related]
9. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
12. Opioids and motor complications in Parkinson's disease.
Samadi P; Bédard PJ; Rouillard C
Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
[TBL] [Abstract][Full Text] [Related]
13. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
14. Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach.
Blandini F
Exp Neurol; 2003 Dec; 184(2):556-60. PubMed ID: 14769348
[No Abstract] [Full Text] [Related]
15. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.
Vamos E; Pardutz A; Klivenyi P; Toldi J; Vecsei L
J Neurol Sci; 2009 Aug; 283(1-2):21-7. PubMed ID: 19268309
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Kostrzewa RM; Kostrzewa JP; Brus R
Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
[TBL] [Abstract][Full Text] [Related]
17. [Current preclinical findings on substances against Parkinson's disease].
Gerlach M; Riederer P
Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease.
Lim CK; Fernández-Gomez FJ; Braidy N; Estrada C; Costa C; Costa S; Bessede A; Fernandez-Villalba E; Zinger A; Herrero MT; Guillemin GJ
Prog Neurobiol; 2017 Aug; 155():76-95. PubMed ID: 27072742
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of Parkinson disease. 1: Standard therapy of motor and non-motor symptoms].
Kuhn W; Müller T
Fortschr Neurol Psychiatr; 1997 Aug; 65(8):361-74. PubMed ID: 9378449
[TBL] [Abstract][Full Text] [Related]
20. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease.
Rice JE; Antic R; Thompson PD
Mov Disord; 2002 May; 17(3):524-7. PubMed ID: 12112201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
